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Aim of the study: Determining the role 
of PET/CT imaging in the evaluation 
of treatment efficacy in primary me-
diastinal B-cell lymphoma (PMBCL). 
Material and methods: Retrospective 
analysis of seven PMBCL patients, 
treated at the University Hospital in 
Krakow, with interim PET/CT after the 
third course of chemo-immunotherapy. 
The analysis was based on the cal-
culation of exact tumour volume and 
metabolic activity, compared with ini-
tial values (directly after diagnosis).   
Results: Patients (five females, two 
males, average age 26.2 years, range 
18–40 years), in clinical stage IIBX at 
diagnosis, were treated with eight cy-
cles of R-CHOP-14 regimen, with radio-
therapy consolidation (7/7) and cen-
tral nervous system prophylaxis (6/7).  
The observed decrease in tumour vol-
ume between the initial staging and 
the interim PET ranged 72–89%. The 
mean ∆SUV
max reduction between ini-
tial (when available) and interim PET 
was 87% (range 84–89%). In 3/7 cas-
es in the interim PET/CT, the uptake of 
the tumour was higher than the liver 
(Deauville Criteria score 4–5), and in 
4/7 it was lower than the liver but 
higher than mediastinal blood pool 
structures (score 3 according to Deau-
ville Criteria). After a median follow-up 
of 58 months – OS and EFS is 100%. 
Conclusions: The excellent clinical 
outcome in the study group corre-
sponds with very good metabolic and 
volumetric response in the interim 
PET. The ∆SUV
max seems to be easier 
in implementation and has a  more 
significant impact than other mea-
surements.
Key words: lymphoma, large B-cell, 
diffuse/radionuclide imaging, tomo- 
graphy, X-ray computed mediastinal 
neoplasms/radiography.
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Introduction
Primary mediastinal B-cell lymphoma (PMBCL) is a rare neoplasm, which 
represents 2–3% of all cases of non-Hodgkin lymphoma. It usually affects 
young females, 20–40 years old, and has a relatively good prognosis with 
modern immune-chemotherapy regimens (over 90% five-year progres-
sion-free survival, based on results of patients treated at the Department of 
Haematology of the University Hospital in Krakow).  
The higher PMBCL mortality rate, described in early publications, could 
have resulted from an inaccurate diagnosis (differential diagnosis with dif-
fuse large B cell lymphoma (DLBCL) – with secondary mediastinal involve-
ment [1, 2]) or inappropriate therapy. Although adding rituximab clearly 
increased response rates and overall survival [3], the role of dose intensi-
ty regimens, and consolidation radiotherapy has not yet been established 
(efficiency vs. adverse effects). 
To allow an adequate comparison of different treatment protocols, it is 
crucial to determine the optimal response assessment, addressing the prob-
lem of residual mass – a common phenomenon at the end of therapy. 18 
F-fluorodeoxyglucose (FDG) PET/CT allows assessment of both the morphol-
ogy and biology of the tumour. It became a standard of care in staging and 
evaluation of treatment outcome in DLBCL patients [4, 5]. In PMBCL [6–11] 
PET/CT has been implemented using the standard response criteria for lym-
phoma [12]. Early response assessment in PET/CT performed after 2–4 cycles 
remains controversial. Initial results in DLBCL were highly optimistic [13, 14], 
but further studies were not coherent in their conclusions [15, 16]. Even few-
er data are available on PMBCL [3, 17, 18]. 
Material and methods
A retrospective analysis of imaging studies was performed in seven se-
quential PMBCL patients treated at the Department of Haematology of the 
University Hospital in Krakow, whose interim PET/CT after the third course 
of chemoimmunotherapy was available. 
Patients included in the analysis were treated with seven or eight cy-
cles of R-CHOP regimen, repeated every 14 days, consolidated by IFRT 
(Involved-Field Radiation Therapy). Additionally, central nervous system 
involvement prevention was implemented: in five cases as intrathecal Dep-
oCyte (4–8 doses), and in one as prophylactic cerebral irradiation.
The protocol included imaging studies at diagnosis (in four cases PET/
CT, in three CT), an early response PET/CT assessment and response assess-
ment four weeks after the completion of chemotherapy and three months 
after radiotherapy. 
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All PET/CT examinations were acquired with the same 
protocol in one centre. For the purpose of this study, im-
ages collected in the DICOM system were retrospectively 
analysed by an independent radiologist. The analysis of CT 
data included: volumetric measurements of the tumour 
(tumour volume = sum of surface areas of the lesion on 
the transverse sections multiplied by thickness of scans) 
and calculation of the SPD (the sum of the products of the 
largest transverse diameters of up to six changes) [19]. In 
the assessment of PET-CT we used the five-point scale, 
defined at the First Consensus Conference in Deauville 
2009 [20], as recommended during the International Con-
ference on Malignant Lymphomas Imaging Working Group 
(ICML recommendations) [12], based on comparison of 
standardised uptake value (SUV) of the lesion with refer-
ence SUV (mediastinal blood pool structures (MBPS) and 
liver uptake). In four patients we additionally calculated 
the ∆SUV
max
 – reduction in the maximum standardised up-
take value at the most intense tumour in two subsequent 
examinations [21], according to the following formula:
∆SUVmax(%) = 100 × (SUVmax[initial]-SUVmax[subsequent]/SUVmax[initial].
Results
Demographics: five women and two men. The median 
age at diagnosis was 28 (range 18 to 40) years. The me-
dian follow-up was 58 months (range 48 to 68 months), 
the progression-free survival (PFS) and the overall survival 
(OS) were both 100%.
The predominant manifestation at diagnosis was a tu-
mour of the upper anterior mediastinum. In some cases, it 
extended to the adjacent regions (Fig. 1). Its largest trans-
verse diameter varied from 8 to 14.7 cm (median 10.3 cm). 
Involvement of cervical or pericardial lymph nodes was 
confirmed in three and two patients, respectively. Involve-
ment of extra-nodal sites was relatively frequent: pleural 
and pericardial effusions (in two and three patients, ac-
cordingly) and pulmonary nodules and lung infiltrations 
(two cases). In the study group nobody had infra-phrenic 
changes. The total volume of the involved masses ranged 
from 151 to 987 cm3 (median 427 cm3). 
A significant decrease of tumour masses and volumes, 
as well as a reduction of the SUV
max
, was observed in the 
course of the treatment. The change was most notable 
during the first cycles of immunochemotherapy (reduction 
of volume at the interim PET/CT ranged from 72 to 89%, 
compared to the initial volume of the tumour). This ten-
dency continued in the following assessments, reaching 
from 23 to 65% one month after the completion of the first 
round of immunochemotherapy. A similar trend and com-
parable values were observed according to the SPD.  The 
tumour volumes, SPD at different stages of the treatment, 
and their changes are summarised in Table 1 and Fig. 2. 
In the interim PET/CT the SUV
max
 of the lesion of every 
patient was above the uptake of the MBPS (mediational 
blood pool structures), with a similar population achieving 
four and three points according to the Deauville Criteria 
(three and four patients, respectively). Despite such dif-
ferences in the FDG uptake, the ∆SUV
max
 between initial 
and interim PET were very high and surprisingly coherent 
(84–89%, median 88%).
In the studied group, there was only one person who 
had SUV
max
 of the tumour remnants lower than the MBPS 
after completion of the therapy (after chemotherapy or – if 
the previous examination was unavailable – at an appro-
priate time after radiotherapy).  Among the four other pa-
tients, for whom PET/CT was performed, in one the SUV
max
 
of the lesions was higher than SUV
max
 of the liver, while for 
the three other patients this value was within the interval 
between SUV
max
 of the liver and that of the MBPS.  The 
changes in SUV
max 
according to the Deauville Criteria are 
presented in Table 2.
Discussion
According to histopathological and genomic findings, 
primary mediastinal B-cell lymphoma is considered to 
derive from a small population of thymus B cells [2]. This 
disease has a unique molecular and clinical characteris-
tic, distinguishing it from DLBCL, more similar to NScHL 
(Nodular Sclerosis classical Hodgkin Lymphoma). Both 
tumours are most common in young adults, and on diag-
nosis present as localised bulky tumours of the anterior 
Fig. 1. CE-CT and PET/CT scan of a patient with PMBCL before the treatment. A bulky mediastinal mass, with extension into the left lung, 
is visible
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mediastinum. In histopathology, fibrosis is a common find-
ing. Moreover, on the PMBCL cells as well on the Hodg- 
kin Reed-Stenberg (HRS) cells surface Ig are often. Both 
tumours are characterised by similar genomic abnormal-
ities, including gains of chromosome 2p and 9p. In addi-
tion, they were described as rare cases of composite or 
sequential NScHL and PMBCL and “mediastinal grey-zone 
lymphomas”, with features between NScHL and PMBCL.
At the moment of diagnosis, primary mediastinal B-cell 
lymphoma manifests as a rapidly progressive tumour in 
the anterior mediastinum, which at the initial staging of-
ten measures more than 10 cm in diameter and can di-
rectly invade the lungs, thorax, pleura, or pericardium. In 
a short time, it results in symptoms of narrowing of the 
airways or great vessels, which may lead to upper vena 
cava syndrome. Despite the local invasiveness, infiltration 
of distant organs at the initial staging is rare. But at the 
time of recurrence, the involvement of extranodal organs, 
such as the liver, kidneys, or central nervous system [2, 22] 
is not uncommon.
CHOP-R-14 based regimens of chemotherapy, comple-
mented by prophylaxis of the central nervous system in-
volvement and involved field radiotherapy (standard treat-
ment in the Department of Haematology of the University 
Hospital in Krakow), have shown good efficacy with an 
acceptable toxicity profile. The superiority of the CHOP-R 
regimens over the CHOP regimens is highly supported and 
widely accepted [23, 24]. However, mediastinal irradia-
tion carries in survivors a high risk of late complications, 
of which secondary malignancies and heart failure are 
particularly dangerous. Conversely, the excellent results 
obtained in a GELA (Groupe d’Etude des Lymphomes de 
l’Adulte) study with different regimens but without  irradi-
ation [25] put the necessity of such consolidation therapy 
into question. Nowadays, in the era of rituximab, the ap-
plication of CHOP-like schemes of chemotherapy is better 
documented. For example, Moskowitz et al. [17] evaluated 
the dose-dense CHOP-R/ICE consolidation chemotherapy 
program, obtaining in three years of observation time 78% 
progression-free survival, and they suggested avoiding ra-
diotherapy and lack of benefits from the interim PET/CT. 
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Table 2. SUVmax of the lesions, according to the Deauville Criteria 
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In contrast, other authors [7–10] supported omitting the 
radiotherapy only in the group of good responders to the 
primary R-CHOP treatment. 
Moreover, clinical decisions are complicated by the fact 
that in this type of lymphoma the residual masses usually 
persist even after successful treatment. There have been 
attempts to determine the prognosis on the basis of their 
volume: in the previous century Smith et al. [26] demon-
strated that a tumour volume greater than 100 cm3 after 
completion of treatment is a statistically significant risk 
factor for recurrence. The same study showed that other 
information from the CT scans (obtained at the presen-
tation and after completion of the first-line treatment) 
was not as important. In our study group, one patient had 
a mediastinal mass larger than 100 cm3 after radiotherapy, 
without any signs of recurrence. 
The next step in assessing the response to therapy was 
evaluating the biology of the cells in residual masses, after 
completion of the therapy. Previous studies [27, 28] have 
shown very high usefulness of PET performed with 18F-flu-
orodeoxyglucose. The idea of this examination is to reveal 
an increased glucose metabolism in vivid lymphoma cells. 
Briefly, according to ICML recommendations [12], the most 
intense uptake in a site of initial disease, if present, should 
be scored according to the Deauville Criteria, taking into 
consideration the radioactivity of the mediastinal blood 
pool and the liver. Unfortunately, there is a high rate of 
false positive results in the case of mediastinal tumours 
relating to, inter alia, thymic hyperplasia in young adults 
after chemotherapy or inflammatory changes.  Accord-
ing to the Lugano classification [4] and ICML recommen-
dations [12], in the studied group there were as many as 
three patients with positive PET, considered as treatment 
failure after completion of the therapy (from five, who had 
undergone PET/CT in this moment), and there was 100% 
PFS during the observation. Thereby, results from the PET 
examination alone do not allow determining the outcome 
and taking decision about  the therapy. Thus, a histological 
confirmation of the relapse in this type of lymphoma is 
often needed.
The prognostic value of interim PET in DLBCL has been 
assessed in earlier studies [15, 16, 29]. However, strong ev-
idence of its role and consistent rules of interpretation, are 
not available. Indeed, it is a direct indicator of individual 
response to therapy, in opposition to pre-therapeutic, pop-
ulation-based indices, such as the International Prognostic 
Index. On the other hand, the high rate of false positive re-
sults caused by inflammatory processes, increased in the 
lesion by immunotherapy, and the effect of granulocyte 
colony-stimulating factor [15, 29], are severe drawbacks. 
Moreover, the usefulness of interim PET in PMBCL – a spe-
cific subtype of DLBCL – has been evaluated only in small 
series of patients [3, 17, 18] treated with different regimes. 
There are two possible approaches to determine the in-
dividual response to therapy by interim PET/CT in DLBCL. 
The first one, highly subjective, is based on visual assess-







 method is more sensitive, 
but with large inter-observer differences in the drawing of 




Only in three cases out of the studied cohort, were the 
Deauville Criteria met, i.e. the SUV
max
 of the tumour in the 
interim PET/CT was lower than the SUV
max
 of the liver in 
the same examination. In the remaining four cases, the 
SUV
max
 of the tumour in the interim PET was higher than 
that of the liver. More promising results were obtained 
from the comparison between the initial staging and the 
interim PET/CT. The changes in tumour volume from the 
beginning of the treatment were absolutely amazing – 
ranging from 72% to 89%. Measurements, according to 
the change in SPD – a value easier for implementation 
than volumetric measurements – were also very high, but 
with greater variability: 59–86%. 
Our findings are in line with recently growing recog-
nition of the importance of volume-based metabolic re-
sponse in DLBCL [30]. Ceriani et al. [31], who addressed the 
PMBCL as a distinct subtype of the disease, checked the 
utility of the metabolic tumour volume (MTV) – defined as 
the best fit between “metabolic edges” and anatomical 
boundaries – and the total lesion glycolysis (TLG), calculat-
ed as a product of SUV
mean
 and MTV.  The authors showed 
that these two measurements in the baseline PET/CT were 
associated with the progression-free survival (PFS) and 
overall survival (OS). In contrast they did not find such cor-




Very promising data was obtained using ∆SUV
max
. In 
our small study group, the obtained results were coherent 
and very high (84–89%). This type of measurement has re-
cently been implemented by some researchers [15, 21, 29, 
32, 33] and has shown a high prognostic value, although 
consistent rules of implementation still need to be deter-
mined [12].
 In conclusion, the results from both rounds of the PET-
CT examination seem to be complementary and important 
in the management of primary mediastinal B-cell lympho-
ma. In the study group data from a single examination 
(size of the lesion, its volume, SUV
max
) were not as import-





, is easiest in implementation among the analysed 
measures, and gives the most coherent results. The useful-
ness of this approach may be very specific for PMBCL be-
cause the behaviour of this neoplasm is not typical. Thus, 
this method of assessment needs further evaluation in 
larger study groups, especially in prospective clinical trials. 
The authors declare no conflict of interest.
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